InMed Pharmaceuticals IncINM
Price$1.35

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $4.5M-2.0% YoYTTM through 31 Dec 2025
Net Income -$12.6MTTM through 31 Mar 2026
Free Cash Flow -$8.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin29.7%
EBITDA Margin-247.8%
Operating Margin-252.4%
Net Margin-278.7%

Returns

-124.1%ROE
-93.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.12x
Net Debt-$5.2Mnet cash position
Cash & Equivalents$5.2M

Quality Metrics

Altman Z-Score-68.44
Piotroski F-Score3 / 9
FCF Margin-191.8%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $4.9M
Diluted EPS-$3.12TTM
'20'21'22'23'24'25'26
FY2026: $-3.02

Dividend

No dividend

Capital Allocation

R&D Spend$3M
Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.